Business, energy, technology, markets and global industry news from Business News Today

CalciMedica

PharmaDeviceNews CalciMedica
Representative image of clinical researchers analysing kidney and respiratory data as CalciMedica redesigns the Auxora KOURAGE trial following a mortality imbalance.
Features & Analysis

Can CalciMedica rescue Auxora after a mortality imbalance threatened its kidney injury trial?

CalciMedica has preserved the clinical future of Auxora after regulators reviewed safety data from the KOURAGE trial, but restarting development is only the beginning of a difficult scientific and financial recovery.

Read More
Pharma & Biotech

Does the FDA’s KOURAGE response restore confidence in CalciMedica’s CRAC platform?

CalciMedica can continue developing Auxora after the FDA reviewed KOURAGE safety data without imposing a clinical hold, but a large financing, major potential dilution and a strategic shift toward pulmonary hypertension redefine the CALC investment case.

Read More